Masseteric hypertrophy?: preliminary report.
Newton JP, Cowpe JG, McClure IJ, Delday MI, Maltin CA.
Br J Oral Maxillofac Surg. 1999 Oct;37(5):405-8. doi: 10.1054/bjom.1999.0075.
Botulinum toxin for masseter hypertrophy.
Fedorowicz Z, van Zuuren EJ, Schoones J.
Cochrane Database Syst Rev. 2013 Sep 9;2013(9):CD007510. doi: 10.1002/14651858.CD007510.pub3.
Masseteric hypertrophy.
Mandel L, Kaynar A.
N Y State Dent J. 1994 Aug-Sep;60(7):44-7.
Bilateral hypertrophy of masseteric and temporalis muscles, our fifteen patients and review of literature.
Graziano P, Dell'Aversana Orabona G, Astarita F, Ponzo LM, Nunziata R, Salzano G, Maglitto F, Solari D, Santella A, Cappabianca M, Iaconetta G, Califano L.
Eur Rev Med Pharmacol Sci. 2016;20(1):7-11.
Neurotoxins.
Ong AA, Sherris DA.
Facial Plast Surg. 2019 Jun;35(3):230-238. doi: 10.1055/s-0039-1688844. Epub 2019 Jun 12.
Neurectomy of the Masseteric Nerve Using an Extra-Oral Approach to Treat Masseter Hypertrophy: Case Report and Literature Review.
Van Der Kelen L, Ureel M, Bauters W, Vermeersch H, Coopman R.
J Oral Maxillofac Surg. 2023 Dec;81(12):1476-1484. doi: 10.1016/j.joms.2023.08.170. Epub 2023 Aug 25.
BENIGN MASSETERIC HYPERTROPHY.
LASH H.
Surg Clin North Am. 1963 Oct;43:1357-61. doi: 10.1016/s0039-6109(16)37094-3.
Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A.
Nikolis A, Enright KM, Rudolph C, Cotofana S.
J Cosmet Dermatol. 2020 Jun;19(6):1294-1300. doi: 10.1111/jocd.13434. Epub 2020 Apr 27.
Bilateral temporalis hypertrophy.
Ali K, Sittampalam G, Malik MA.
Int J Oral Maxillofac Surg. 2010 Mar;39(3):305-7. doi: 10.1016/j.ijom.2009.09.005.
Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.
Seok J, Koh YG, Hong JK, Yun SH, Kim DH, Son HS, Choi SY, Yoo KH, Lee YW, Kim BJ.
Dermatol Surg. 2024 Jun 1;50(6):527-533. doi: 10.1097/DSS.0000000000004146. Epub 2024 Mar 8.
